Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of metyrapone on cardiovascular risk factors in adrenal incidentalomas with subclinical/mild Cushing's syndrome
2024-518932-34-00Phase 4Authorised
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of metyrapone in Cushing's syndrome, Adrenal incidentaloma (AI) and hypertension (HTN) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Reduction of antihypertensive therapy while maintaining blood pressure control at 12 months. Planned start Nov 2024; status: authorised.
02
Drugs
metyrapone
03
Conditions
Cushing's syndromeAdrenal incidentaloma (AI)hypertension (HTN)
Beyond the preview
Go deeper on 2024-518932-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518932-34-00.